bellus health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. its lead project is blu-5937, a drug candidate for the treatment of chronic cough. bellus health also has economic interests in other partnered drug development projects. blu-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the p2x3 receptor, a clinically validated target for chronic cough. blu-5937 is a promising best-in-class drug candidate that has the potential to help millions of chronic cough patients who do not respond to current therapies. rights to blu-5937 were obtained under a license agreement with the neomed institute in february 2017. chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. it is estimated that, in the united states alone, more than 2.7 million patients suffer from chronic cough that is
Company profile
Ticker
BLU
Exchange
Website
CEO
Roberto Bellini
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEUROCHEM INC
SEC CIK
BLU stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jun 23
25-NSE
Exchange delisting
28 Jun 23
6-K
Material Change Report
28 Jun 23
6-K
GSK completes acquisition of BELLUS Health
28 Jun 23
6-K
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
16 Jun 23
6-K
Notice of Annual and Special Meeting of Shareholders
6 Jun 23
6-K
Notice of Annual and Special Meeting of Shareholders
2 Jun 23
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Aug 23
SC 13G
COMMODORE CAPITAL LP
30 Mar 23
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 23
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G
GOLDMAN SACHS GROUP INC
13 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
SC 13G
PICTET ASSET MANAGEMENT SA
3 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q2 2023
6.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 15 |
| Opened positions | 4 |
| Closed positions | 93 |
| Increased positions | 1 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 5.44 bn |
| Total shares | 8.70 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Integrated Core Strategies | 4.06 mm | $32.72 mm |
| Artal International S.C.A. | 3.70 mm | $0.00 |
| Fonds De Solidarite Des Travailleurs Du Quebec | 472.53 k | $1.45 mm |
| Carmignac Gestion | 220.88 k | $3.26 bn |
| Vazirani Asset Management | 109.62 k | $1.62 bn |
| BCS Barclays | 76.45 k | $1.13 mm |
| Gardner Lewis Asset Management L P | 14.70 k | $216.65 mm |
| Simplex Trading | 11.72 k | $172.00 k |
| Alberta Investment Management | 11.00 k | $161.94 mm |
| Amundi | 10.06 k | $148.26 mm |